Abstract
Immune checkpoint inhibitors are breakthrough monoclonal antibodies in cancer therapy developed against mechanisms that suppress the immune response. After the devastating effects of chemotherapy, these specific agents have given hope to cancer patients. However, every drug has side effects itself and these useful drugs have theirs too. In addition to systemic side effects, there are also neurological side effects, the frequency of which is increasing day by day, although they are reported very rarely for now. Here, we present a case that has myositis-myocarditis-myasthenia gravis overlap syndrome. These three syndromes are very rare even to be seen alone, which are detected together. This syndrome with a very high mortality was brought under control in this case, and the fact that nivolumab treatment can be continued makes the case even more interesting. In this article, it is aimed to draw attention to this serious triple complication of immune checkpoint inhibitors and to review the relevant literature on a case basis.
Copyright
Association for Helping Neurosurgical Sick People. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-Non Derivative-Non Commercial License, permitting copying and reproduction so long as the original work is given appropriate credit.
Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
